Based on cash, and cash equivalents as of September 30, 2025, and current operating plans, the Company expects its cash runway to be sufficient to fund operations into 2029.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMRX:
- IMRX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- 3 Best Stocks to Buy Now, 11/3/2025, According to Top Analysts
- Apple upgraded, Comcast downgraded: Wall Street’s top analyst calls
- Immuneering initiated with an Outperform at Leerink
- Immuneering price target raised to $12 from $10 at Mizuho